About Vericel

Advanced cell therapies for sports medicine and severe burn care

#

Vision

Vericel is committed to improving the lives of patients with serious conditions by developing and manufacturing innovative cell therapies and specialty biologics.

#

Mission

Vericel is passionately committed to meeting significant patient and healthcare provider needs by providing potentially life-enhancing cell therapies to patients with serious medical conditions.

#

Values

Vericel believes in encouraging each employee to exceed the expectations of the patients we serve, their healthcare providers, and the shareholders who support our efforts.


Previous Next

Management Team

Dominick Colangelo

Dominick Colangelo

President & CEO

Nick joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

Mike Halpin

Mike Halpin

Chief Operating Officer

Mike joined Vericel in April of 2017 with over 28 years of regulatory, quality assurance, and clinical research experience with a variety of medical device, combination product, small molecule, biologic, and advanced therapy technologies. Prior to joining Vericel, Mike was with Sanofi and Genzyme Corporation; most recently as vice president, North American region regulatory head with responsibility for Sanofi Genzyme’s rare disease, immuno-inflammatory, multiple sclerosis and other business unit products. Mike has also served as vice president, regulatory affairs for Genzyme’s biosurgery division, with regulatory oversight of all biosurgery and cell and gene therapy products, including Carticel®, Epicel®, and MACI®. Prior to Genzyme, Mike held a number of regulatory, quality, and clinical affairs positions at several medical device companies, including Abbott/MediSense, C.R. Bard, and Abiomed. Mike received his master’s degree in biomedical engineering and bachelor’s degree in biochemistry from the University of Virginia.

Dr. Jonathan Hopper, MB ChB

Dr. Jonathan Hopper, MB ChB

Chief Medical Officer

Jon Hopper is a seasoned industry executive with previous experience as a surgeon and government regulator. He qualified in medicine in the UK in 1987 and trained as an Orthopaedic and Trauma surgeon, gaining additional clinical experience in Accident and Emergency, Sports Medicine and Trauma Intensive Care. Jon became a Fellow of the Royal College of Surgeons of Edinburgh in 1992. In 1997, he joined the UK’s Senior Civil Service as a senior medical officer at the UK’s Department of Health, regulating medical device manufacturers and advising senior government officials and Ministers of State. Jon attained the degree MBA (Health Executive) from the University of Keele 2003. In 2006, Jon joined the medical device industry and moved to the USA in 2009. He has held various Global Medical Affairs and Clinical Development Executive roles for ConvaTec, Stryker, Osiris Therapeutics and Ferring Pharmaceuticals. Jon joined Vericel in August 2018 and leads the Clinical Development, Pharmacovigilance and Medical Affairs functions.

Roland DeAngelis

Roland DeAngelis

Senior Vice President, Commercial Operations

Roland has over 20 years of experience with Vericel’s brands, having joined the company in 2014 by virtue of the acquisition of Sanofi-Genzyme’s cell therapy and regenerative medicine business unit. During his Vericel tenure, Roland has held roles in sales and marketing leadership. He led the commercial team responsible for the successful launch of MACI® in the U.S. as well as the growth of Epicel® and the burn care franchise. While with Sanofi-Genzyme, Roland held a variety of commercial roles including product development, sales training, product and key account management, advocacy development and global marketing. Prior to Sanofi-Genzyme, Roland held positions as group product manager for the knee arthroscopy and reconstruction product line with Smith & Nephew Endoscopy and as product design engineer with Acufex Microsurgical. In his early career, he was a systems engineer in the defense industry with Hughes Aircraft and other defense contractors. Roland holds a BS degree in Mechanical Engineering and Applied Mechanics from the University of Rhode Island.

Heidi Hassen

Heidi Hassen

Vice President, Human Resources

Heidi joined Vericel in September of 2010 and is responsible for leading the overall administration and strategic direction of Vericel’s Human Resources function. Heidi has held HR leadership positions for over 25 years across several industries, including computer storage technology, industrial computer manufacturing, and biotechnology.  Prior to joining Vericel she was employed by Cayman Chemical, where she was responsible for the company’s global Human Resources operations and served as a fiduciary of the Cayman Chemical Retirement Savings Plan.  Prior to Cayman Chemical she led the HR organization for Xycom Automation (Pro-face America), a manufacturer of industrial PCs. She received a B.A. in Employment Relations, College of Social Science, from Michigan State University.

Sean Flynn

Sean Flynn

Vice President and General Counsel

Sean joined Vericel in 2019, having served as corporate and litigation counsel for nearly 20 years in both the public and private sectors.  Prior to joining Vericel, Sean held the position of Vice President and General Counsel of Verastem, Inc. where he was responsible for all legal matters and supported the launch and commercialization of Copiktra®.  Sean also served as Associate General Counsel and Chief Compliance Officer for ABIOMED, Inc. during a period of rapid revenue and market growth.  In that capacity, Sean handled a wide variety of business and legal matters for the organization, while maintaining responsibility for the compliance readiness of the company on a global scale.  Prior to joining ABIOMED, Sean served for seven years as a federal prosecutor with the Offices of the United States Attorney for the Eastern District of California and the Eastern District of New York.  Sean began his legal career as a litigator with Bingham McCutchen LLP, after clerking for the Honorable Ruggero J. Aldisert, Senior Circuit Judge, United States Court of Appeals for the Third Circuit.  Prior to beginning his legal career, Sean served as an Air Defense Artillery Officer in the United States Army, having graduated from the United States Military Academy at West Point in 1995.

Board of Directors

Robert L. Zerbe, M.D.

Robert L. Zerbe, M.D.

Chairman since October 2012
Director since January 2006

Dr. Robert Zerbe joined the Vericel Board of Directors in January 2006 and has been its Chairman since October 2012.  Until July 2016, Dr. Zerbe served as the Chief Executive Officer of QUATRx Pharmaceuticals Company, a venture‑backed drug development company, which he co‑founded in 2000. Prior to his role at QUATRx, Dr. Zerbe held several senior executive management positions with major pharmaceutical companies, including Eli Lilly and Company and Pfizer. During his tenure at Eli Lilly, Dr. Zerbe’s clinical research and development positions included Managing Director, Lilly Research Center U.K., and Vice President of Clinical Investigation and Regulatory Affairs.  He joined Parke‑Davis in 1993, becoming Senior Vice President of Worldwide Clinical Research and Development.  In this capacity, Dr. Zerbe led the clinical development programs for a number of key products, including Lipitor® and Neurontin®.  Dr. Zerbe received his M.D. from the Indiana University School of Medicine and he has completed post‑doctoral work in internal medicine, endocrinology and neuroendocrinology at Indiana University and the National Institutes of Health.  Dr. Zerbe serves on the boards of directors of Metabolic Solutions Development Company and Cirius Therapeutics, both private companies focusing on metabolic diseases.

Alan L. Rubino

Alan L. Rubino

Director since September 2005

Mr. Rubino has served as President and Chief Executive Officer of RenovaCare, Inc., a publicly held biotechnology company, since November 2019.  Prior to RenovaCare, Mr. Rubino served as Chief Executive Officer and President of Emisphere Technologies, Inc., Chief Executive Officer and President of New American Therapeutics, Inc., Chief Executive Officer and President of Akrimax Pharmaceuticals, LLC, and President and Chief Operating Officer of Pharmos Corporation. Mr. Rubino has continued to expand upon a highly successful and distinguished career that includes Hoffmann‑La Roche, Inc., where he was a member of the U.S. Executive and Operating Committees and an executive officer.  During his Hoffman-La Roche tenure, Mr. Rubino held a series of key executive positions in marketing, sales, business operations, supply chain and human resource management and was assigned executive committee roles in marketing, project management, and globalization of the worldwide pharmaceuticals business.  Mr. Rubino has also held senior executive positions at PDI, Inc. and Cardinal Health Mr. Rubino holds a B.A. in economics from Rutgers University with a minor in biology/chemistry and has completed post‑graduate educational programs at the University of Lausanne and Harvard Business School.  Mr. Rubino currently serves as a member of the boards of directors of SANUWAVE Health, Inc. and Genisphere, Inc.

Heidi Hagen

Heidi Hagen

Director since August 2013

Heidi M. Hagen is Co-Founder of, and Advisor to, Vineti, Inc., a privately‑held company that develops and commercializes cloud‑based software platforms for ordering, manufacturing and delivering personalized medicines.  Previously, Ms. Hagen served as interim Chief Commercial Officer at ZappRx, Inc. from January 2015 to June 2015.  Ms. Hagen also served as Global Chief Operating Officer at Sotio LLC, a biotechnology company developing new therapies for the treatment of cancer and autoimmune diseases using its immunotherapy platform and proprietary cell‑based technologies, from March 2013 to April 2014.  Before joining Sotio, Ms. Hagen served for ten years as Senior Vice President of Operations at Dendreon Corporation, where she was responsible for manufacturing and supply chain operations.  Prior to joining Dendreon, Ms. Hagen spent nearly ten years at Immunex Corporation, where she held several positions in drug development and supply chain and operations management.  Since June 2019, Ms. Hagen has served as a member of the boards of directors of Ziopharm Corporation, a publicly held company focused on developing the next generation of immuno-oncology gene and cell therapies, and Lykan Biosciences, a privately-held company focused on cell and gene manufacturing.  Ms. Hagen earned a B.S. in cell and molecular biology, M.S. in bioengineering, and MBA from the University of Washington.

Steven Gilman, Ph.D.

Steven Gilman, Ph.D.

Director since January 2015

Dr. Steven Gilman has been a member of the Vericel Board of Directors since 2015.  Dr. Gilman served as the Chairman of the board of directors and Chief Executive Officer of ContraFect Corporation until his retirement in April 2019.  He previously served as Executive Vice President, Research & Development and Chief Scientific Officer at Cubist Pharmaceuticals from September 2010 until its acquisition by Merck & Co., in January 2015.  Prior to joining Cubist, Dr. Gilman served as Chairman of the board of directors and Chief Executive Officer of ActivBiotics, Inc., a privately-held biopharmaceutical company.  Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles, including Vice President and General Manager, Inflammation.  Prior to Millennium, he was Group Director at Pfizer Global Research and Development and has also held scientific, business, and academic appointments at Wyeth Pharmaceuticals, Inc., Cytogen Corporation, Temple Medical School, and Connecticut College.  Dr. Gilman currently serves on the boards of directors of ContraFect Corporation, SCYNEXIS, Inc., Akebia Therapeutics, Inc. and Momenta Pharmaceuticals, Inc.  Dr. Gilman earned a B.A. in microbiology from Miami University of Ohio and Ph.D. and M.S. degrees in microbiology from Pennsylvania State University.  He is an author of over 60 publications and seven U.S. patents.

Kevin McLaughlin

Kevin McLaughlin

Director since January 2015

Kevin McLaughlin is Senior Vice President, Chief Financial Officer and Treasurer of Acceleron Pharma – a position he has held since 2010.  Previously, Mr. McLaughlin served as Senior Vice President and Chief Financial Officer of Qteros, Inc., a cellulosic biofuels company.  He was also a Co-founder of Aptius Education, Inc., a publishing services company, and from 2007 through 2009, served as the Chief Operating Officer and a director.  From 1996 through 2007, Mr. McLaughlin held several executive positions with PRAECIS Pharmaceuticals, Inc.  He joined PRAECIS as their first Chief Financial Officer where he had responsibility for private financings, partnership financings and the company’s initial public offering.  Later, Mr. McLaughlin became Chief Operating Officer, and then President and Chief Executive Officer, while serving as a member of the board of directors.  In this capacity, he was responsible for negotiating the sale of the company to GlaxoSmithKline.  He began his career in senior financial roles at Prime Computer and Computervision Corporation.  Mr. McLaughlin is also a member of the board of directors and Chairman of the audit committee of Stealth Biotherapeutics Corp.  Mr. McLaughlin received a B.S. in business from Northeastern University and an MBA from Babson College.

Paul Wotton, Ph.D.

Paul Wotton, Ph.D.

Director since January 2015

Dr. Paul Wotton is Chief Executive Officer and a member of the board of directors of Obsidian Therapeutics, Inc. – a position he has held since April 2019.  Previously, Dr. Wotton was the founding President and Chief Executive Officer of Sigilon Therapeutics, Inc., a privately held cell therapeutics company, which began in May 2016.  Prior to that, Dr. Wotton served as the President, Chief Executive Officer and a member of the board of directors of Ocata Therapeutics, Inc. until its acquisition by Astellas Pharma US, Inc. in February 2016.  Prior to Ocata, he served as President and Chief Executive Officer and as a member of the board of directors of Antares Pharma, Inc., as Chief Executive Officer of Topigen Pharmaceuticals, and as the Global Head of Business Development of SkyePharma PLC.  Earlier in his career, Dr. Wotton held senior level positions at Eurand International BV, Penwest Pharmaceuticals, Abbott Laboratories and Merck, Sharp and Dohme.  Dr. Wotton serves as Chairman of the board of directors of Cynata Therapeutics Limited and is also past Chairman of the Emerging Companies Advisory Board of BIOTEC Canada.  In 2014, Dr. Wotton was named Ernst & Young Entrepreneur of the Year for Life Sciences, New Jersey.  Dr. Wotton received his Bachelor’s in Pharmacy, with honors, from University College London, his Ph.D. in pharmaceutical sciences from the University of Nottingham, and his MBA from Kingston Business School.

Dominick Colangelo

Dominick Colangelo

President & CEO

Nick joined Vericel in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development, and commercialization of products across a variety of therapeutic areas. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.

A history of transformation through restoration

1987

First cell therapy

Epicel®, the 1st autologous cell therapy, is introduced by BioSurface Technologies for the treatment of patients with deep dermal or full thickness burns.

1995

Transformative medicine

Genzyme, a pioneer in the development and delivery of transformative therapies for patients affected by rare and debilitating diseases acquires BioSurface Technologies and renames the company: Genzyme Tissue Repair.

1995

First for orthopedics

Carticel®, the first autologous cell therapy for the treatment of cartilage lesions in the knee is commercialized in Europe by Genzyme Tissue Repair.

1997

Restorative treatment

Carticel receives the first BLA for a cell therapy, ushering in an entirely new mode of treatment for orthopedic injuries.

1998

Streamlined delivery

MACI®, a cellular therapy similar to Carticel but delivered on a collagen membrane, is first performed in Germany.

2004

Global presence

Genzyme acquires Verigen of Germany, the developer of MACI, along with global rights to the product, securing its commitment to next generation cellular repair therapies for cartilage defects.

2011

Biologics in the spotlight

Sanofi, a top five global pharmaceutical company, acquires Genzyme in a deal worth 20 billion US dollars.

2013

First in Europe

MACI becomes the first tissue-engineered Advanced Therapy and Medicinal product approved by the European Medicines Agency.

2014

A move toward the future

Vericel, a longtime leader in adult stem cell therapies and personalized medicine acquires global rights to Carticel, Epicel and MACI making it a worldwide leader in cellular therapies.

2016

First in USA

The FDA approves MACI, the first product utilizing tissue engineering to grow cells on scaffolds using healthy cartilage from the patient’s own knee.

Tomorrow

A commitment to innovation

Vericel is proud of our pioneering role in helping to develop the cellular therapy category. Vericel will continue to innovate and deliver on the promise of treatment derived from a patient’s own regenerative cells.

Partnering with Vericel

Vericel Corporation is dedicated to the development of advanced cell therapies for the treatment of patients with severe diseases and conditions. Vericel currently markets two advanced cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is a third generation autologous chondrocyte implant for the treatment of cartilage defects in the knee. Epicel® (cultured epidermal autografts) is a permanent skin replacement for full thickness burns greater than or equal to 30% of total body surface area. At this time Vericel is seeking partners to commercialize MACI and Epicel outside of the United States. Vericel is also seeking to acquire, co-develop or in-license products which leverage either the company’s existing sports medicine and burn care commercial capabilities, or the company’s proven cell therapy development, manufacturing and commercialization capabilities.

For more information about partnering with Vericel

Contact Us >

NASDAQ: VCEL

$25.9624 0.4224 (1.65%)
Day High: $26.82
Day Low: $25.6
Volume: 1035557
3:45 PM on
December 1, 2020
Copyright West LLC. Minimum 15 minutes delayed.

Company Presentation